(VIANEWS) – The Market ended the session with AELIS FARMA (AELIS.PA) rising 10.09% to €6.00 on Thursday, after two sequential sessions in a row of losses. CAC 40 dropped 0.92% to €7,431.96, after two sequential sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.
AELIS FARMA’s last close was €5.45, 61.83% below its 52-week high of €14.28.
About AELIS FARMA
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
Earnings Per Share
As for profitability, AELIS FARMA has a trailing twelve months EPS of €-0.39.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.17%.
More news about AELIS FARMA (AELIS.PA).
